×

Nyrada Inc.

Nyrada is a preclinical stage, drug discovery, and development company, specialising in novel small molecule drugs to treat cardiovascular, neurological, and inflammatory/autoimmune diseases.

The Company has two main programs, each targeting market sectors of significant size and considerable unmet clinical need. These are a cholesterol-lowering drug and a drug to treat brain injury, specifically traumatic brain injury and stroke. Nyrada Inc. ARBN 625 401 818 is a company incorporated in the state of Delaware, USA, and the liability of its stockholders is limited.

Spotlight Videos

News

Nyrada gears up for Phase I clinical trials

Nyrada (ASX:NYR), a drug discovery company focused on small molecule therapies, has announced the successful completion of critical safety studies for its lead candidate NYR-BI03. The drug, designed to treat neuroprotective and cardioprotective conditions such as stroke and traumatic brain injury, is on track for its first-in-human clinical trials in late 2024.

Read More